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Background: Prolonged intracellular calcium elevation contributes to sensitization of nociceptors and chronic pain
in inflammatory conditions. The underlying molecular mechanisms remain unknown but store-operated calcium
entry (SOCE) components participate in calcium homeostasis, potentially playing a significant role in chronic pain
pathologies. Most G protein-coupled receptors activated by inflammatory mediators trigger calcium-dependent
signaling pathways and stimulate SOCE in primary afferents. The aim of the present study was to investigate the
role of TRPC3, a calcium-permeable non-selective cation channel coupled to phospholipase C and highly expressed
in DRG, as a link between activation of pro-inflammatory metabotropic receptors and SOCE in nociceptive pathways.
Results: Using in situ hybridization, we determined that TRPC3 and TRPC1 constitute the major TRPC subunits
expressed in adult rat DRG. TRPC3 was found localized exclusively in small and medium diameter sensory neurons.
Heterologous overexpression of TRPC3 channel subunits in cultured primary DRG neurons evoked a significant increase
of Gd3+-sensitive SOCE following thapsigargin-induced calcium store depletion. Conversely, using the same calcium
add-back protocol, knockdown of endogenous TRPC3 with shRNA-mediated interference or pharmacological inhibition
with the selective TRPC3 antagonist Pyr10 induced a substantial decrease of SOCE, indicating a significant role of TRPC3
in SOCE in DRG nociceptors. Activation of P2Y2 purinoceptors or PAR2 protease receptors triggered a strong increase in
intracellular calcium in conditions of TRPC3 overexpression. Additionally, knockdown of native TRPC3 or its selective
pharmacological blockade suppressed UTP- or PAR2 agonist-evoked calcium responses as well as sensitization of DRG
neurons. These data show a robust link between activation of pro-inflammatory receptors and calcium homeostasis
through TRPC3-containing channels operating both in receptor- and store-operated mode.
Conclusions: Our findings highlight a major contribution of TRPC3 to neuronal calcium homeostasis in somatosensory
pathways based on the unique ability of these cation channels to engage in both SOCE and receptor-operated calcium
influx. This is the first evidence for TRPC3 as a SOCE component in DRG neurons. The flexible role of TRPC3 in calcium
signaling as well as its functional coupling to pro-inflammatory metabotropic receptors involved in peripheral
sensitization makes it a potential target for therapeutic strategies in chronic pain conditions.
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The transient receptor potential (TRP) gene superfamily
consists of a large set of tetrameric channels permeable
to monovalent and/or divalent cations. In mammals, sev-
eral of the 28 TRP channel family members are expressed
in subpopulations of peripheral sensory neurons and are
involved in the transduction of thermal, mechanical and
chemical stimuli, with documented roles in normal and
pathological nociception [1].
However, both the cellular physiology of TRP canonical
(TRPC) channels in sensory neurons and their exact role
in nociception have yet to be clarified. The TRPC subtypes
are non-selective calcium-permeable cationic channels
ubiquitously expressed in most tissues. They integrate sev-
eral types of intracellular stimuli, including PLC and PKC
activity, DAG levels, intracellular calcium levels and PIP2
levels into changes in membrane potential and calcium
entry [2]. Of particular interest is the role of TRPC3 in
somatosensory pathways because of recent evidence
pointing to an almost exclusive expression of this chan-
nel in IB4+ nociceptors, a large population of C-fiber
nonpeptidergic sensory neurons known to contribute to
inflammatory pain [3].
One of the hallmarks of inflammatory pain is the
sensitization of peripheral nociceptors innervating the
inflamed area. During the inflammation process, induced
either by chemical agents, injury or infection, a stimulus-
response shift is observed in nociceptors, resulting in an
enhanced response to noxious stimuli (hyperalgesia) or in
a nocifensive response to normally innocuous stimuli
(allodynia) [4]. The many chemicals released at the site of
inflammation form a “soup” that triggers oedema, itchi-
ness, redness, and sensitization [5]. This “inflammatory
soup” consists of a diverse set of signaling molecules
which are capable of inducing hyperexcitability by activat-
ing their cognate membrane receptors at the surface of
nociceptors [6]. Many of these receptors include well char-
acterized Gq-protein coupled receptors (GqPCR), such as
the P2Y2 purinoceptor, bradykinin B2 and protease-
activated PAR2 receptor [6,7]. The coupling of these
GqPCRs to the phospholipase C (PLC) pathway produces
two bioactive compounds upon stimulation, diacylglycerol
(DAG) and inositol trisphosphate (IP3), both of which act
to increase intracellular calcium levels through two dis-
tinct mechanisms: one is referred to as store-operated
calcium entry (SOCE) and involves the activation of cal-
cium channels by IP3-induced depletion of endoplasmic
reticulum calcium stores. The other, receptor-operated
calcium entry (ROCE), involves the activation of calcium-
permeable channels directly by DAG [8-11]. Hence, the
production of these two secondary messengers via PLC ac-
tivation results in both intracellular calcium levels increase
and enhanced entry of extracellular calcium across the
plasma membrane following depletion of calcium stores.Crucially, one common resulting action of these two path-
ways is the downstream activation of calcium-dependent
protein kinase C (PKC) isoforms mediating the phos-
phorylation and sensitization of voltage- and ligand-gated
channels involved in acute and chronic inflammatory
responses [12,13].
The signaling pathways of known pro-inflammatory
receptors in DRG neurons such as P2Y2 and PAR2 are
not completely characterized, but an increase in intracellu-
lar calcium levels is critical for the activation of their
downstream effectors [8,10,14]. It has recently been shown
that an abnormal persistent increase in intracellular cal-
cium levels mediates the transition from acute to chronic
pain in inflammatory pancreatitis [15,16]. Thus the regu-
lation of intracellular calcium levels, primarily through
SOCE, could be a key mechanism in preventing
sensitization. While most TRPC channel subtypes play
a role in ROCE, some members of the TRPC family
have been implicated in SOCE signaling as well [17,18].
Moreover, members of the TRPC3/6/7 channel subfam-
ily have been shown to be functionally coupled to the
PLC pathway in various mammalian cell lines [19-22].
In addition, TRPC channels have been linked to the ac-
tivation of pro-inflammatory bradykinin B2 receptors in
non-neural cells [23,24], suggesting that this class of
calcium-permeable cation channels might be involved
in both SOCE and ROCE signaling mechanisms down-
stream of the PLC pathway in neurons as well.
The present report focuses on the ill-defined role of
TRPC channels in mammalian sensory pathways. Our
data show that TRPC3, highly expressed in adult rodent
DRG, is coupled to several classes of pro-inflammatory
metabotropic receptors and plays a significant role in cal-
cium homeostasis and sensitization in primary nocicep-
tors, through its involvement in both SOCE and ROCE.
Results and discussion
Expression of the TRPC gene family in rat DRG
To determine the expression profile of TRPC subunits in
adult rat DRG, RT-PCR was performed in order to poten-
tially detect all 7 mammalian TRPC members (TRPC1-7).
As shown in Figure 1A, TRPC1 and TRPC3 genes appear
to be strongly transcribed, while other TRPC subunit
mRNAs were found at low levels or not at all. To deter-
mine the level of TRPC expression using a complemen-
tary approach, we performed in situ hybridization
targeting each of the TRPC transcripts in rat spinal sec-
tions containing the DRGs. As illustrated in Figure 1B,
we confirm that TRPC1 and TRPC3 are the only two
major transcripts in the TRPC family present at high
levels in DRGs. Furthermore, mRNA detection in situ
with cellular resolution in DRG and trigeminal ganglia
sections allowed us to assess that TRPC3 expression is
mainly confined to the subpopulation of small and
Figure 1 TRPC family gene expression in sensory ganglia.
(A) TRPC mRNA detection using a RT-PCR screen against TRPC1-7 in
adult rat DRG. TRPC1 and TRPC3 are the major subunits expressed in
DRG, along with low levels of TRPC6 and little or no signal for TRPC
2, 4, 5 and 7. (B) In situ expression profile of all TRPC family members
at the whole DRG and spinal cord level. TRPC1 and TRPC3 are
expressed at high levels in DRGs, with minimal detection in the
spinal cord. Low but significant TRPC6 expression is also observed at
the DRG level. (C) Emulsion staining with cellular resolution clearly
shows that TRPC3 mRNA is localized in a subpopulation of small and
medium diameter neurons (arrows) in DRG and trigeminal ganglia
(TGG). Representative negative small-diameter and large-diameter
neurons are also indicated (stars). Scale bar = 50 μm.
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majority of which are C-fiber nociceptors, in agreement
with findings in the mouse somatosensory pathways
published recently [18,25,26]. TRPC1 function has been
linked to ubiquitous STIM1-dependent SOCE [27-29] and
our histological data indicate that its expression is not re-
stricted to a specific population of sensory neurons in
DRG, therefore we focused our investigation on DAG-
gated TRPC3 channels localized in primary nociceptors.
TRPC channels are involved in SOCE in DRG neurons
The activation of the PLC pathway by pro-inflammatory
GPCRs leads to the production of cytosolic IP3 that,through the gating of its receptor-channel IP3R located
at the surface of the ER, induces the release of calcium
from intracellular stores. This initiates SOCE, the pri-
mary mechanism responsible for calcium homeostasis,
through the activation of the ER transmembrane calcium
sensors STIM1 and STIM2. Activated STIM proteins ag-
gregate with each other and translocate to the plasma
membrane where they interact with several types of cal-
cium channels, including the ubiquitous Orai1 calcium-
selective channel and specific TRPC channel subtypes,
inducing them to open their gates and causing an influx
of extracellular calcium, further increasing intracellular
calcium levels and replenishing ER calcium stores. This
increase in intracellular calcium levels is thought to con-
tribute to the activation of calcium-sensitive switches
and pathways that mediate inflammatory hypersensitisa-
tion, most notably PKC [30,31]. To determine if TRPC
channels play a role in this response, we first assessed
the presence of SOCE in cultured DRG neurons by
treating them with 1 μM thapsigargin for 7 minutes in
calcium-free solution, leading to passive diffusion of ER
calcium into the cytoplasm (Figure 2A), and hence mim-
icking the physiological process of store-depletion and
the activation of SOCE. The addition of the Orai blocker
Gd3+ at 1 μM to the perfusion solution clearly produced
a robust decrease in calcium influx of approximately 50%
(Δ340/380 = 0.147 ± 0.034 for control vs. 0.072 ± 0.015 for
Gd3+ condition), as shown in Figure 2A. The remaining
calcium influx may indicate the involvement of TRPC
channels. To test if TRPC channels contribute to SOCE
in DRGs, we used the generic TRPC and SOCE pharma-
cological blocker SKF96365 at 30 μM for 50 minutes.
The addition of SKF96365 completely abolishes SOCE
(Δ340/380 = 0.267 ± 0.050 for control vs. 0.017 ± 0.006
for SKF96365), providing evidence for the recruitment
of TRPC channels in the SOCE response in rat DRGs
(Figure 2B). Additionally, the activation of TRPC3 by
the DAG analog OAG (50 μM, 3 min) is also potently
inhibited by SKF96365 (Δ340/380 = 0.144 ± 0.026 for con-
trol vs. 0.038 ± 0.007 for SKF96365, Figure 2C), suggesting
a specific role for DAG-gated TRPC3 channels in the
SOCE response observed.
Contribution of TRPC3 to SOCE in DRG neurons
TRPC3 has been implicated in SOCE in pancreatic cells
[32], prostate smooth muscle cells [33], HEK-293 cells
[34], and hippocampal neuronal cells [35]. To check if
TRPC3 has any role in SOCE response in DRG neurons,
we opted for RNA interference with a subunit-specific
GFP-tagged TRPC3 shRNA. Its knockdown efficacy
was measured at close to 70% in OAG-evoked TRPC3-
mediated calcium responses in heterologous expression
(Δ340/380 = 0.346 ± 0.028 for control vs. 0.106 ± 0.019

































































Figure 2 Contribution of TRPC channels to SOCE in DRG neurons. All traces are representative calcium responses recorded using the Fura-2
ratiometric method. (A) Thapsigargin (Thaps, 1 μM, 7 min) evokes a biphasic SOCE response in cultured rat DRG neurons (control). The first phase
reflects the release of calcium from ER stores while the second phase reflects the influx of extracellular calcium, upon calcium re-addition to the
perfusion solution (calcium add-back protocol), via Orai and/or TRPC channels. The addition of the Orai blocker Gd3+ (1 μM, 7 min) resulted in a
significant decrease of calcium influx by 50%, suggesting a possible role for other channels including TRPCs in the remaining response (n = 8-19,
P < 0.05). (B) SKF96365 (30 μM), a general SOCE and TRPC blocker, completely blocks SOCE (n = 14-23, P < 0.0005). (C) Effect of SKF96365 on TRPC3
activity. Activation of TRPC3 with the DAG analog OAG (50 μM, 3 min), is significantly inhibited by SKF96365 (approximately 75%), indicating a major
role for TRPC3 in the TRPC component of the thapsigargin-induced SOCE response observed in DRG neurons (n = 15-18, P < 0.01).
Alkhani et al. Molecular Pain 2014, 10:43 Page 4 of 12
http://www.molecularpain.com/content/10/1/43validated, this TRPC3 shRNA was transfected into cul-
tured primary DRG neurons that were recorded 4-5
days post transfection. With respect to controls, TRPC3
transcript knockdown reduced SOCE response by ap-
proximately 42% (Δ340/380 = 0.281 ± 0.022 for control vs.
0.161 ± 0.037 for TRPC3 shRNA, Figure 3B). Conversely,
overexpressing TRPC3 (TRPC3 OE) by transfecting DRG
neurons with TRPC3 cDNA produced a large increase in
store-mediated calcium influx (Δ340/380 = 0.147 ± 0.034
for control vs. 0.275 ± 0.037 for TRPC3 OE, Figure 3C).
Application of the TRPC3 blocker Pyr10 (10 μM, 15 min)
inhibited store-dependent calcium influx by approximately
50% (Δ340/380 = 0.162 ± 0.027 for control vs 0.077 ± 0.016
for Pyr10, Figure 3D), mirroring our shRNA knockdownresults. Furthermore, the addition of both the Orai blocker
Gd3+ and TRPC3 blocker Pyr10 almost completely abol-
ished SOCE (Δ340/380 = 0.162 ± 0.027 for control vs.
0.006 ± 0.004 for Pyr10 + Gd3+), indicating that the two
major components of SOCE in DRG nociceptors are the
Orai and TRPC3 channels (Figure 3D). This is the first
direct evidence showing the major role that TRPC3 plays
in SOCE response in DRG sensory neurons. However, the
role of TRPC3 as a SOCE channel has been controversial
[32,35-38]. As TRPC channels integrate many intracellular
signals, these discrepancies could simply be related to the
intracellular environment of different cell types and/or to
species specificities. We report here a strong contribu-






























































































Figure 3 TRPC3 participates in SOCE in DRG neurons. (A) TRPC3 shRNA-mediated knockdown was validated in a functional assay to determine
the inhibitory effect of the shRNA on OAG-evoked calcium entry in DRG neurons (n = 9-11, P < 0.0001). (B) shRNA-mediated knockdown of TRPC3 in
the SOCE assay clearly shows a strong contribution of this channel to the overall calcium influx. A decrease of approximately 42% is observed
(n = 13-27, P < 0.05). (C) Heterologous overexpression of TRPC3 (OE) in DRG neurons produced a drastic increase in SOCE-mediated calcium
influx of approximately 85% (n = 16-19, P < 0.01). (D) The inhibition of TRPC3 activity by the selective blocker Pyr10 (10 μM, 15 min) also resulted
in a strong decrease of SOCE activity, with calcium influx dropping approximately 50% (n = 34-39, P < 0.01). The cumulative inhibition of both
Orai and TRPC3 with Gd3+ and Pyr10, respectively, almost completely abolished SOCE response in DRG (n = 18-21, P < 0.001).
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ROCE. This bi-modal functionality of TRPC3 makes it a
versatile and unique channel subtype involved in calcium
homeostasis and calcium-dependent signaling.
TRPC3 involvement in P2Y2 receptor transduction
After determining that TRPC3 contributes to SOCE, we
sought to investigate its link to pro-nociceptive pathways.The activation of the purinoceptor P2Y2 by pro-
inflammatory nucleotides such as ATP or UTP initiates the
PLC pathway through Gq-coupling, activating both SOCE
and ROCE by generating IP3 and DAG, respectively. To
examine if TRPC3 contributes to P2Y2-mediated calcium
signaling, we applied 100 μM UTP, a selective agonist for
P2Y2 receptors [39], on primary DRG cultures for 7 minutes.
The addition of Gd3+, and hence blockade of Orai function,
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of calcium to the perfusion solution. However, in these condi-
tions, Orai contribution appears to be limited at about 35% of
the overall calcium entry evoked by UTP (Δ340/380= 0.113±
























































Figure 4 Functional coupling between TRPC3 and UTP/P2Y2 signaling
the calcium-free perfusion solution activates P2Y2 receptors, which initiate
Orai component of the UTP-evoked response, which accounts for approxim
blockade of TRPC3 specifically with Pyr10 (10 μM, 15 min) resulted in a dra
(n = 25-28, P < 0.001). (C) shRNA-mediated knockdown of TRPC3 induced in s
(D) Heterologous overexpression of TRPC3 (OE) resulted in 90% increase of ca
activity and P2Y2 transduction (n = 24-45, P < 0.001).Application of the TRPC3 antagonist Pyr10 decreased P2Y2-
mediated calcium entry by as much as 60% (Δ340/380=
0.317± 0.039 for control vs. 0.127 ± 0.023 for Pyr10, Figure 4B).
This significant contribution of TRPC3 to UTP-evoked





































in DRG neurons. (A) The addition of 100 μM UTP for 7 minutes to
both SOCE and ROCE responses. The addition of Gd3+ removes the
ately 35% of the overall calcium influx (n = 17-19, P < 0.05). (B) The
stic decrease of UTP-evoked calcium entry, resulting in 60% inhibition
imilar decrease of P2Y2-mediated calcium entry (n = 34-46, P < 0.0001).
lcium influx in the UTP response, indicating a strong link between TRPC3
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a similar decrease in calcium entry was observed (Δ340/
380 = 0.417 ± 0.025 for control vs. 0.139 ± 0.013 for
TRPC3 shRNA-treated cells, Figure 4C). Confirming a
functional link between TRPC3 and P2Y2 receptor ac-
tivity, overexpression of TRPC3 subunits in DRG neu-
rons induced a significant increase in UTP-evoked
calcium influx (Δ340/380 = 0.135 ± 0.026 for control vs.
0.257 ± 0.025 for TRPC3 OE), as shown in Figure 4D.
These results clearly indicate that TRPC3 plays a major
role in P2Y2 function, and they substantiate for the first
time a robust functional link between TRPC3 and the
pro-inflammatory nucleotides ATP/UTP in peripheral
pain pathways.
Significant contribution of TRPC3 to PAR2-mediated
calcium signaling
To further generalize the notion of an association of
TRPC3 with pro-inflammatory mediators, we sought to test
a functional link of TRPC3 to another metabotropic recep-
tor involved in peripheral sensitization in inflammatory
conditions, the Gq-coupled protease-activated receptor 2
(PAR2). Much like P2Y2, PAR2 is also coupled to the PLC
pathway and to a rise in intracellular calcium levels lead-
ing to the activation of PKC and other calcium sensitive
processes, which are thought to contribute significantly to
inflammatory sensitization [40-42]. We stimulated cul-
tured DRG neurons with the PAR2 selective agonist
AC55541 at 100 μM for 7 minutes along with the Orai
blocker Gd3+. Contrary to the results with P2Y2, the Orai
calcium channels did not appear to be a major source of cal-
cium influx in the PAR2-mediated response (Δ340/380 =
0.114 ± 0.013 for control vs. 0.082 ± 0.016 for Gd3+,
Figure 5A). However, much in line with the P2Y2 results,
the addition of Pyr10 induced a significant decrease of cal-
cium influx, around 66%, (Δ340/380 = 0.246 ± 0.038 for con-
trol vs. 0.083 ± 0.015 for Pyr10), as shown in Figure 5B. The
major contribution of TRPC3 to PAR2 signaling was also
demonstrated by shRNA-mediated knockdown experiments
which showed a decrease in calcium influx similar to that of
pharmacological inhibition with Pyr10 (Δ340/380 = 0.441 ±
0.025 for control vs. 0.149 ± 0.023 for TRPC3 shRNA,
Figure 5C). This was further confirmed by the overexpres-
sion of heterologous TRPC3 that increased calcium influx
more than twofold (Δ340/380 = 0.197 ± 0.012 for control
vs. 0.463 ± 0.021 for TRPC3 OE, Figure 5D).
PAR2- and P2Y2-mediated sensitization of nociceptors is
TRPC3-dependent
We tested the contribution of TRPC3 to peripheral
sensitization by sensitizing DRG neurons with the PAR2
agonist AC55541 and the P2Y2 agonist UTP. Patched cul-
tured nociceptors showed a membrane resting potential be-
tween -58 mV and -70 mV. In current-clamp configuration,they were able to consistently fire action potentials during a
current injection protocol (200 pA, 50 ms duration, 4 s in-
tervals, Figure 6A). While current injection of 50 pA did not
evoke action potentials in control conditions (Figure 6B),
stimulation with both AC55541 (100 μM) and UTP
(100 μM) sensitized 56% (14/25) of neurons to these sub-
threshold depolarizations (Figure 6C). Application of the se-
lective TRPC3 antagonist Pyr10 (10 μM) suppressed 50 pA
current-induced action potentials in 66.7% (6/9) of sensi-
tized neurons (Figure 6D) in a reversible manner and with-
out altering intrinsic excitability (Figure 6E). The application
of Pyr10 alone did not affect resting membrane potential or
firing properties (data not shown).
Taken together, these results strengthen the notion that
TRPC3 channels are recruited in several pro-inflammatory
metabotropic pathways, at least those triggered by the nu-
cleotides ATP/UTP and trypsin-like proteases which are
components of the “inflammatory soup”. TRPC3 channels
also play a significant role in store- as well as receptor-
operated calcium-dependent mechanisms in rat DRG neu-
rons. The reported rise in basal intracellular calcium levels
during inflammatory conditions is thought to mediate an
increase in PKC activity, which has been shown to play a
major role in neuronal sensitization [30,31,43]. TRPC3 con-
tributes significantly to this process as shown by our
in vitro sensitization data. Nevertheless, we cannot exclude
a role of TRPC1 in the TRPC3-dependent ROCE and
SOCE described here. Due to the documented heteromeri-
zation of store-linked TRPC1 with TRPC3 [17,34,35], it is
likely that TRPC1 + 3 heteromers contribute to SOCE in
DRG neurons as well. TRPC3 being a non-selective cation
channel, its abnormal activation due to an upregulation of
pro-inflammatory GPCRs such as P2Y2 and PAR2 could
also mediate neuronal hyperexcitability through sustained
depolarization. Although the conditional knockout of both
TRPC3 and TRPC6 in Nav1.8+ DRG neurons did not
induce behavioral deficits in acute pain responses [44],
the mechanisms by which TRPC3 mediates calcium-
dependent sensitization of nociceptors in inflammatory
conditions will remain to be deciphered.
Conclusions
Our data provide evidence that the DAG-gated and PLC-
linked TRPC3 channel is involved in Orai-independent
SOCE in adult rat primary nociceptors in DRG, where it is
the major TRPC subunit expressed along with TRPC1.
We show that in these neurons TRPC3 is also functionally
coupled to several inflammatory transductions triggering
calcium-dependent pathways and peripheral sensitization,
including UTP/P2Y2 and proteases/PAR2 signaling com-
plexes. We propose that this unique dual contribution to
SOCE and ROCE defines the calcium-permeable TRPC3
channel as a key regulator of calcium homeostasis in DRG



























































































Figure 5 TRPC3 is linked to proteases/PAR2 transduction in DRG neurons. (A) Addition of 100 μM AC55541 to the calcium-free perfusion
solution activates PAR2 receptors, which initiate both SOCE and ROCE responses. Treatment with Gd3+ removed the Orai component, which produced
a small but non-significant decrease in calcium influx (n = 22-24, P > 0.05). (B) The selective inhibition of TRPC3 with Pyr10 (10 μM, 15 min) resulted in a
drastic decrease (66%) of AC55541-evoked calcium entry (n = 19-29, P < 0.001). (C) shRNA-mediated knockdown of TRPC3 induced a similar decrease
in PAR2-mediated calcium entry of approximately 66% (n = 24-73, P < 0.0001). (D) Heterologous overexpression of TRPC3 (OE) increased by 135% the
calcium influx following PAR2 activation, indicating a strong link between TRPC3 activity and PAR2 function (n = 18-26, P < 0.0001).
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Tissue extraction for RNA isolation
All experimental procedures were approved by the McGill
University Animal Care Committee and were in compli-
ance with the guidelines of the Canadian Council on
Animal Care. DRGs were collected from adult Sprague-Dawley rats (4-8 weeks, Charles River) and suspended
in Dulbecco’s modified Eagles medium containing 10%
heat inactivated fetal bovine serum (Invitrogen), 1%
penicillin and streptomycin, and 1% L-glutamine. Fol-
lowing extraction, DRG neurons were dissociated with














PAR2 agonist + UTP 
PAR2 agonist + UTP + Pyr10 
vehicle 
Figure 6 TRPC3 is involved in peripheral sensitization induced
by PAR2 and P2Y2 receptors. Intrinsic excitability of a
representative DRG nociceptor recorded sequentially under current-
clamp conditions (RMP = -67 mV). (A) Firing of action potentials was
consistently triggered by current pulses (200 pA; 50 ms duration)
injected at fixed time intervals (n = 25). No firing was detected in
conditions of subthreshold current injection (50 pA; 50 ms duration)
(B) unless the cells were first sensitized by application of both PAR2
agonist AC55541 (100 μM) and P2Y2 agonist UTP (100 μM) (n = 14/25)
(C). (D) Treatment with the specific TRPC3 antagonist Pyr10 (10 μM)
suppressed this sensitization effect in most neurons (n = 6/9). (E) At the
end of each recording, cells were tested for viability and displayed
normal firing activity after Pyr10 washout (n = 6).
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diameter neurons. Dissociated neurons were plated on
poly-D-lysine and laminin coated 60 mm tissue culture
dishes, and left overnight at 37°C and 5% CO2 to recover.
The following day, cells were collected with 1% trypsin-
EDTA and centrifuged. The pellet was used to extract
total RNA using Qiagen’s RNeasy Mini Kit as described
by the manufacturer. To eliminate possible genomic
DNA contamination, total RNA samples were treated
with RNase-Free DNase (Qiagen) in accordance with
the manufacturer’s protocol.
cDNA synthesis and RT-PCR
Total RNA DRG extracts were used as templates to
synthesize single-strand cDNAs. Random hexamers
(Invitrogen) and RNaseOUT Recombinant Ribonuclease
Inhibitor (Invitrogen) were used with the Omniscript RT
Kit (Qiagen) to reverse-transcribe the cDNA templates
according to the manufacturer’s recommendations. cDNAs
were used in subsequent PCR reactions to determine
the expression of TRPC gene family members in adult
rat DRGs.
In situ hybridization
Rat tissue was obtained from adult male Sprague-Dawley
rats (n = 3). TRPC1 and TRPC3 mRNAs were detected by
radioactive in situ hybridization (ISH), as previously de-
scribed [45]. Anti-sense 35S-radiolabeled riboprobes were
directed to the 1616-2177, 2246-2706, 1269-1797, 1561-
1976, 2129-2512, 1891-2207 and 1797-2560 sequences of
the rat TRPC 1, 2, 3, 4, 5, 6, 7 mRNA, respectively. These
riboprobes were designed to detect selectively each TRPC
subunit transcript and sense probes were used as negative
controls.
Primary cultures for calcium imaging and
electrophysiology
DRG extraction (n = 30-40) was carried out on 1-2 month
old Sprague-Dawley rats. Following extraction, DRG neu-
rons were dissociated with fire-polished glass pipettes, fil-
tered with 40 μm filters, and suspended in Dulbecco’s
modified Eagles medium (DMEM) containing 10% heat
inactivated fetal bovine serum (Invitrogen), 1% penicillin
and streptomycin, and 1% L-glutamine. Nontransfected
homogenized DRG neurons were plated on 35 mm glass
bottom dishes coated with poly-D-lysine (Sigma-Aldrich)
and laminin (BD Bioscience) at a density of 50-100,000
cells/dish, and incubated with 2 ml of complete DMEM
media, at 37°C in 5% CO2 until recording and imaging.
For patch-clamp recording, DRG ganglia were mech-
anically triturated using fire-polished Pasteur pipettes as
well, but after each trituration, partially dissociated cells
were briefly centrifuged (1000 rpm), and the supernatant
was collected. Dissociated cells were plated on 35-mm
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with laminin and poly-D-lysine. Cells were incubated for
24 h to 48 h at 37°C in 5% CO2 before electrophysio-
logical recording.
Overexpression and shRNA-mediated knockdown
Adult rat DRGs (n = 35-40) were transiently transfected
using Amaxa Rat Neuron Nucleofector Kit (Lonza) and
Nucleofector I (Amaxa), in accordance with the manufac-
turer’s guidelines. Nucleofected neurons were plated on
35 mm glass bottom dishes coated with poly-D-lysine and
laminin for subsequent calcium imaging. Cultured neurons
were maintained in Neurobasal-A medium (Invitrogen)
supplemented with B-27 (Invitrogen), 1% penicillin and
streptenomycin, and 1% L-glutamine, 17.5 μg/ml uridine
(Sigma-Aldrich) and 7.5 μg/ml of 5-fluoro-2’-deoxyuridine
(Sigma-Aldrich). Media was replaced every 48-72 hours
and cultures were incubated at 37°C in 5% CO2.
Heterologous expression of TRPC3 was induced with
co-nucleofection of 6 μg of mouse TRPC3 in pcDNA3
along with 2 μg of GFP plasmid. Recording experiments
were carried out on transfected GFP+DRG neurons 48-72
hours post-transfection. TRPC3-specific shRNA construct
(Origene) was used to interfere with the translation of the
endogenous TRPC3 subunits as previously described [46].
Knockdown was performed by transient transfection of
6 μg GFP-tagged TRPC3 shRNA using Nucleofector I as
described above. Cultures were incubated at 37°C in 5%
CO2 for a period of 4-6 days for maximal knockdown
before recording.
Calcium imaging
DRG neurons were plated on glass bottom dishes coated
with poly-D-lysine- and laminin-coated dishes at a density
of 50-100,000 cells/dish. Prior to recording, the cells were
loaded with 5 μM Fura-2 AM (Molecular Probes) + 0.1%
BSA for 40 min and then washed for 30 min with the
extracellular solution (containing in mM: 152 NaCl, 5
KCl, 2 CaCl2, 1 MgCl2, 10 HEPES and 10 glucose, pH 7.4)
at 37°C in 5% CO2. During recording, the cells were con-
stantly perfused with the extracellular solution and stimu-
lated with the appropriate agonist. Cells were selected
using an inverted TE2000-U microscope (Nikon) equipped
with 40X oil-immersion objective [CFI super(S) fluor,
Nikon]. Fura-2 AM was excited at 340 nm and 380 nm
every second and emission at 510 nm was detected by a
high-resolution cooled CCD camera (Cool Snap-HQ,
Roper Scientific/Photometrics) interfaced to a Pentium
III PC. The variation in intracellular calcium levels was
determined by the ratio of fluorescence at 340 nm and
380 nm (340/380 ratio) calculated using the Metafluor
7.0 software (Molecular Devices). For each cell, agonist-
induced increase in intracellular calcium (Δ340/380)
was determined by subtracting the baseline ratio fromthe peak ratio of the response, divided by the baseline.
All experiments were conducted at room temperature.
The SOCE and TRPC blocker SKF96365 (Tocris) was
used. The compound Pyr10, a selective TRPC3 antag-
onist, was provided by Dr. Groschner (Institute of
Biophysics, Medical University of Graz, Austria) [47].
Store-operated calcium signaling was induced in cultured
DRGs by applying the sarco/endoplasmic reticulum Ca2+
ATPase blocker thapsigargin (1 μM) for 7 minutes in
calcium-free perfusion solution. Fluctuation of intracellu-
lar calcium levels was measured using single-cell micro-
fluorescence. The P2Y2 agonist UTP (Tocris) and the
small-molecule PAR2 agonist AC55541 (Tocris) were
added to the calcium-free perfusion solution (100 μM for
7 min) to activate their respective Gq-coupled receptors in
DRG neurons.
Patch-clamp electrophysiology
Whole-cell patch-clamp recordings on DRG neurons
were conducted 24 hr post plating at room temperature.
The internal solution of the pipette, pH 7.2, contained
(in mM): 130 K-gluconate, 1 MgCl2, 10 HEPES, 5 EGTA,
3 MgATP, and 0.4 GTP. The bath solution, pH 7.4, con-
tained (in mM): 152 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10
HEPES, and 10 glucose. Patch pipettes had a tip resistance
of 3–8 MΩ. Electrophysiological recording experiments
were performed using an Axopatch 200B amplifier and
digitized with a Digidata 1322A interface (Molecular De-
vices). Traces were acquired and analyzed using pClamp
8.2 software (Molecular Devices). Recordings were low-
pass filtered at 2 kHz and 5 kHz in voltage- and current-
clamp configurations, respectively. Under current-clamp,
action potentials were electrically-induced (50-200 pA)
with 50 ms depolarizing pulses at fixed time intervals.
Data analysis
Student’s t tests were used for assessing statistical signifi-
cance between two experimental conditions. Differences
were considered significant at P < 0.05.
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